

Myocardial Left Ventricular Dysfunction in Patients with Systemic Lupus Erythematosus: New Insights from Tissue Doppler and Strain Imaging

SEBASTIAN J. BUSS, DAVID WOLF, GRIGORIOS KOROSOGLOU, REGINA MAX, CELINE S. WEISS, CHRISTIAN FISCHER, DIETER SCHELLBERG, CHRISTIAN ZUGCK, HELMUT F. KUECHERER, HANNS-MARTIN LORENZ, HUGO A. KATUS, STEFAN E. HARDT, and ALEXANDER HANSEN

ABSTRACT Objective. Systemic lupus erythematosus (SLE) is associated with high cardiovascular morbidity and mortality. Cardiovascular involvement is frequently underestimated by routine imaging techniques. Our aim was to determine if new echocardiographic imaging modalities like tissue Doppler (TDI), strain rate (SRR), and strain (SRI) imaging detect abnormalities in left ventricular (LV) function in asymptomatic patients with SLE.

Methods. Sixty-seven young patients with SLE (mean age 42 ± 10 yrs) without typical symptoms or signs of heart failure or angina, and a matched healthy control group ($n = 40$), underwent standard transthoracic echocardiography, TDI, SRR, and SRI imaging of the LV as well as assessment of disease characteristics.

Results. Despite findings within the normal range on routine standard 2-dimensional echocardiography, SLE was associated with significantly impaired systolic and diastolic myocardial velocities of the LV measured by TDI [mean global TDI: systolic (s): 2.9 ± 0.9 vs 3.9 ± 0.7 cm/s, $p < 0.05$; early (e): 4.3 ± 1.5 vs 6.3 ± 1.3 cm/s, $p < 0.05$; late (a): 2.9 ± 0.8 vs 3.4 ± 0.8 cm/s, $p < 0.05$; values \pm SD]; SRR (s): -0.8 ± 0.1 vs -1.1 ± 0.1 s⁻¹; e: 1.1 ± 0.2 vs 1.6 ± 0.3 s⁻¹; a: 0.7 ± 0.1 vs 1.0 ± 0.2 s⁻¹; all $p < 0.05$); and SR ($-15.11 \pm 2.2\%$ vs $-19.7 \pm 1.9\%$; $p < 0.05$) compared to the control group. Further, elevated disease activity, measured with the ECLAM and the SLEDAI score, resulted in significantly lower values for LV longitudinal function measured by SRR and SR, but not by TDI.

Conclusion. SLE is associated with a significant impairment of systolic and diastolic LV longitudinal function in patients without cardiac symptoms. New imaging modalities provide earlier insight into cardiovascular involvement in SLE and seem to be superior to standard echocardiography to detect subclinical myocardial disease. (First Release Dec 1 2009; J Rheumatol 2010;37:79–86; doi:10.3899/jrheum.090043)

Key Indexing Terms:

ECHOCARDIOGRAPHY
HEART FAILURE

STRAIN IMAGING

TISSUE DOPPLER
SYSTEMIC LUPUS ERYTHEMATOSUS

Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease associated with high cardiovascular morbidity and mortality that primarily affects young

women^{1–4}. Myocardial involvement occurs in 8%–14% of patients, and all cardiac structures may be involved. However, the detection of myocardial involvement in patients with SLE is difficult since clinical signs and symptoms are nonspecific, and myocardial involvement may be present in completely asymptomatic patients⁵. In this regard, standard methods for evaluating cardiac function used in clinical practice often lack the sensitivity to detect myocardial abnormalities in SLE^{6–9}. Thus, the prevalence of myocardial involvement in patients with SLE may be significantly underestimated and may be an important contributor to cardiovascular morbidity and mortality.

Because myocardial architecture is intricate, global left ventricular (LV) function is more complex, with radial, longitudinal, and torsional components^{10–13}. In patients with heart failure, longitudinal LV function represents an independent prognostic variable of survival^{14–19}, and atrioventricular displacement during the cardiac cycle constitutes an

From the Department of Cardiology and Rheumatology, University of Heidelberg, Heidelberg, Germany.

S.J. Buss, MD; D. Wolf, MD; G. Korosoglou, MD, Department of Cardiology; R. Max, MD, Department of Rheumatology; C. Weiss, MD; C. Fischer, Department of Cardiology; D. Schellberg, PhD, Department of Visceral and General Surgery and Department of Psychosomatic and General Internal; C. Zugck, MD, Department of Cardiology, University of Heidelberg; H.F. Kuecherer, MD, Head, Department of Cardiology, Kliniken im Naturpark Altmühlthal, Eichstätt; H.M. Lorenz, MD, Head, Department of Rheumatology; H.A. Katus, MD, Head, Department of Cardiology; S.E. Hardt, MD, Department of Cardiology, University of Heidelberg; A. Hansen, MD, Vice Head, Department of Cardiology, Kliniken im Naturpark Altmühlthal.

Address correspondence to Dr. S.J. Buss, Department of Cardiology, Angiology and Pulmology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.

E-mail: sebastian.buss@med.uni-heidelberg.de

Accepted for publication August 25, 2009.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2010. All rights reserved.

important component of global function of the heart²⁰ and is thought to be reduced early in the progression of several pathologic conditions²¹⁻²³.

Tissue Doppler imaging (TDI) is a relatively new ultrasonographic technique that measures regional systolic and diastolic myocardial velocities^{24,25} and has been used for quantitative analysis of global and regional myocardial function^{26,27}. TDI can assess impairment of myocardial function in left ventricular hypertrophy and stress-induced ischemia, providing important prognostic information^{15,16,28}. Strain imaging (SRI) is a new technique derived from TDI that allows the determination of velocity gradients between 2 points in space²⁹. The resulting contraction variable is independent of passive tethering effects or drawing motion from other regions and therefore appears promising for quantification of regional myocardial function³⁰.

To date there is relatively limited evidence that SLE may be accompanied by a decrease in the systolic and diastolic function of the LV³¹⁻³⁴. Further, to our knowledge there is no published report on the incremental value of strain imaging techniques for the early detection of cardiac involvement in adults with SLE. We sought to determine whether new echocardiographic methods are sensitive enough to assess subclinical myocardial involvement in SLE and whether such involvement is related to aspects of this complex disease (disease activity, serological markers, disease duration).

MATERIALS AND METHODS

Patient selection and enrolment. Sixty-seven young patients with SLE treated at our outpatient clinic and 40 age and sex matched healthy controls were enrolled into the study. Diagnosis of SLE was based on criteria defined by the American College of Rheumatology³⁵. The consecutive patients were visited by 2 rheumatologists (RM, HML) and were included after informed consent. The study was approved by the institutional review board. The presence of cardiovascular risk factors (hypertension, hyperlipidemia, diabetes mellitus, and cigarette smoking) and clinical disease activity based on European Consensus Lupus Activity Measurement (ECLAM) and the SLE Disease Activity Index (SLEDAI) score were obtained. An ECLAM score > 2 ³⁶ and a SLEDAI score > 10 ^{18,19} were considered indicative of a more active disease. Blood samples were investigated determining renal function, C-reactive protein (CRP), anti-dsDNA antibodies, antinuclear antibodies, and erythrocyte sedimentation rate (ESR) as biochemical marker for disease activity.

All patients were in stable clinical condition and under optimized therapy. To avoid potential confounding effects of non-SLE related myocardial complications we excluded patients with typical symptoms or signs of heart failure, significant valvular disease, dilated cardiomyopathy, reduced ejection fraction of $< 55\%$, obvious wall motion abnormalities, severe diastolic dysfunction, pericardial abnormalities, history or symptoms of coronary artery disease (CAD), myocardial infarction, evidence of ischemic heart disease by any stress test or coronary angiography, bundle branch block, atrial fibrillation, serum creatinine > 1.5 mg/dl, or inadequate performance on echocardiograms.

Standard ultrasound examination. Two-dimensional (2D) transthoracic echocardiographic examinations were performed with a commercial ultrasound machine (iE33, Philips Medical Systems, Bothell, WA, USA). Three consecutive cardiac cycles of each view were acquired during breath-hold

and stored digitally. The heart rate and blood pressure were measured in supine position prior to the echocardiographic examination.

Great care was taken to obtain an optimal visualization, e.g., to avoid apical foreshortening and to maximize the length from base to apex. The LV dimensions were measured according to recently published recommendations of the American Society of Echocardiography³⁷. End-diastolic and end-systolic LV volumes and ejection fraction were determined by manual tracing of end-systolic (smallest LV shape) and end-diastolic endocardial borders (largest LV shape) using apical 4-chamber and 2-chamber views, employing the modified Simpson's method for biplane assessment. Pulsed Doppler echocardiography of transmitral flow velocities was performed, positioning a sample volume at the level of the mitral tips to measure the peak velocities of early (E) and late (A) filling waves and deceleration time (DT) of E. Cardiac output and cardiac index were calculated from the stroke volume estimated using the modified Simpson's method. The LV mass was indexed either for the body surface area or its growth relation with height (height^{2.7})^{38,39}.

Tissue Doppler and strain imaging data acquisition. 2D color tissue Doppler recordings with second harmonic imaging were collected with high frame rates (100–170 frames/s) during brief breath-hold, from the apical 4-chamber, 2-chamber, and long-axis views. Pulsed-wave tissue Doppler imaging (PW-TDI) was performed, the sample volume was placed on the lateral mitral annulus in the apical 4-chamber view, and the systolic (s), early (e), and late (a) peak diastolic velocities were measured. Three consecutive beats were measured and averaged for each measurement. The cardiac cycles were recorded as 2D color video loops, and the acquired raw data were saved for offline analysis (Xcelera and QLab, Philips Medical Systems). The inferoseptal, anterolateral, inferior, anterior, and inferolateral (posterior) walls were investigated for longitudinal systolic peak values for TDI, strain (SR), and strain rate (SRR) imaging. Diastolic peak early (e) and late (a) diastolic values for SRR and TDI were also measured.

The region of interest was evaluated using “M-Line” sample volumes (7.5 mm wide), which were placed reaching from the basal over the middle segments towards the apex, in the apical transthoracic views of the LV, excluding the apical regions of the LV, to avoid angle-dependent underestimation (at least $< 30^\circ$). The “M-Line” was then tracked manually and adjusted frame by frame. We considered the sample volume position to be acceptable when the SR waveforms were reproducible over 3 consecutive cardiac cycles. The analysis of the raw data images allows determination of TDI, SR, and SRR curves from the same sample volume at the same time in the same position of the images. A mean value for each wall was determined, as well as a value for the TDI in the basal segments. The analyses of the echocardiographic examinations were performed by the investigators in a blinded manner.

Intra- and interobserver variability. To examine intraobserver variability, a sample of 20 representative echocardiographic examinations for the estimation of TDI and strain parameters were randomly selected for masked review by the same investigator. To examine interobserver variability a coinvestigator blinded to the clinical information and the results of the first investigator examined 20 randomly selected echocardiographic studies for the estimation of TDI and strain parameters.

Statistics. Differences among the groups were assessed with the chi-square test for categorical variables. Comparisons among groups were made using Student's t-test with a Bonferroni correction and one-way factorial ANOVA, with post-hoc testing for multiple comparisons where appropriate. The differences were considered significant after applying the conservative Bonferroni-Holm procedure, to adjust the nominal alpha niveau of $p < 0.05$. Additionally throughout the t-test a Satterthwaite correction was used. Linear regression analyses and a correlation test (either Pearson's or Spearman's method) were performed to assess univariate relations. Data are expressed as mean values \pm SD. Statistical significance was accepted at the $p < 0.05$ level.

RESULTS

Clinical findings. The clinical characteristics are shown in Table 1. The composition of patients in the study and control groups was comparable with respect to age, sex, blood pressure, and heart rate. Among subjects with SLE 21% had arterial hypertension. The median ECLAM score was 3. Current or former use of prednisone was present in 90% of patients, whereas other immunosuppressive therapy was less common (azathioprine in 11%, cyclosporine 10%, mycophenolic acid 10%, cyclophosphamide 8%, and methotrexate 10%). Hydroxychloroquine had been used by 60% of patients.

2D echocardiography. LV wall thicknesses, chamber dimensions, and myocardial mass were higher in patients with SLE than in the reference group (Table 2), resulting in a higher relative LV mass and prevalence of LV hypertrophy ($p < 0.05$). In agreement with others⁴⁰, in our study even SLE patients who were normotensive had greater LV mass than controls (161 ± 36 g vs 138 ± 23 g, respectively; $p < 0.05$; Table 2); moreover, the presence of both SLE and hypertension resulted in a further increase of LV mass (187 ± 38 g; $p < 0.05$).

Biplane estimation of LV ejection fraction revealed a slightly reduced — albeit within the normal range — ejection fraction in the SLE group compared to healthy controls (Table 2). Patients with SLE had greater LV end-diastolic dimension (EDD), greater LV end-systolic dimension (ESD), and a reduced fractional shortening compared to controls. Left atrial dimensions were significantly larger in SLE patients (Table 2). Interestingly, 2 classical characteristics for longitudinal function, MAPSE (mitral annular plane systolic excursion) and TAPSE (tricuspid annular plane systolic excursion), of LV and RV, were already significantly reduced in patients with SLE compared to controls (Table 2).

Indices of transmitral flow are shown in Table 2. Similar to most of the 2D echocardiographic features, no standard Doppler flow measurement differentiated the 2 groups. As anticipated, SLE patients showed a significant reduction in

Table 1. Characteristics of patients with SLE and the control group.

	SLE, n = 67	Control, n = 40	p
Age, yrs	42 ± 10	41 ± 10	NS
Male, %	6	7.5	NS
Systolic pressure, mm Hg	125 ± 19	121 ± 17	NS
Diastolic pressure, mm Hg	80 ± 11	76 ± 10	NS
Body surface area, m ²	1.74 ± 0.2	1.71 ± 0.2	NS
BMI, kg/m ²	24.7 ± 5	23.1 ± 3	NS
Heart rate, bpm	74 ± 13	72 ± 10	NS
Hypertension, %	19	0	< 0.05
Diabetes mellitus, %	0	0	NS
Hyperlipidemia, %	7	12.5	NS
Current smoking, %	9	10	NS

BMI: body mass index; NS: not significant.

Table 2. Comparison of myocardial structure and function in patients with SLE and the control group with 2-dimensional echocardiography.

	SLE, n = 67	Control, n = 40	p
LA, mm	34.1 ± 4.8	31.4 ± 4.0	< 0.05
ESD, mm	29.5 ± 3.8	27.0 ± 2.8	< 0.05
EDD, mm	46.4 ± 3.3	45.5 ± 2.8	NS
SWT, mm	10.0 ± 1.1	9.2 ± 0.9	< 0.05
PWT, mm	9.8 ± 1.0	9.0 ± 2.8	NS
EF, %	59.0 ± 3.1	60.6 ± 2.7	NS
ESV, ml	50.9 ± 9.6	43.6 ± 7.7	< 0.05
EDV, ml	124.6 ± 24.6	110.5 ± 16.7	< 0.05
SV, ml	73.7 ± 16.4	66.9 ± 10.0	NS
FS, %	0.36 ± 0.1	0.4 ± 0.1	NS
Cardiac output, l/min	5.4 ± 1.4	4.8 ± 0.8	NS
Cardiac index, l/min*m ²	3.1 ± 0.8	2.8 ± 0.5	NS
PW-E, cm/s	76.8 ± 19.7	71.9 ± 13.2	NS
PW-A, cm/s	60.4 ± 22.1	54.7 ± 14.0	NS
DT-E, ms	201.2 ± 42.2	201.4 ± 24.1	NS
PW-TDI-s, cm/s	8.6 ± 1.7	12.6 ± 1.4	< 0.05
PW-TDI-e, cm/s	11.7 ± 3.4	15.8 ± 2.9	< 0.05
PW-TDI-a, cm/s	8.7 ± 2.6	9.4 ± 2.5	NS
E/e	7.1 ± 3.6	4.7 ± 1.1	< 0.05
sPA, mm Hg	25.8 ± 4.5	23.6 ± 3.2	< 0.05
MAPSE, cm	1.5 ± 0.3	1.8 ± 0.2	< 0.05
TAPSE, cm	2.0 ± 0.5	2.3 ± 0.3	< 0.05
LV mass (LVM), g	160.7 ± 35.7	137.9 ± 22.6	< 0.05
LV mass index, LVM/BSA	92.6 ± 18.7	81.3 ± 10.9	< 0.05
LV mass index, LVM/m ^{2.7}	41.7 ± 9.7	35.1 ± 5.2	< 0.05
RWT	0.423 ± 0.04	0.396 ± 0.05	< 0.05

DT-E: deceleration time of mitral inflow; EF: left ventricular ejection fraction; EDD: left ventricular end-diastolic dimension; ESD: left ventricular end-systolic dimension; EDV: left ventricular end-diastolic volume; ESV: left ventricular end-systolic volume; FS: fractional shortening; LA: diameter of left atrium; LV: left ventricular; MAPSE: mitral annular plane systolic excursion; PW-A: peak velocity of late diastolic mitral inflow; PW-E: peak velocity of early diastolic mitral inflow; PCWP: estimated pulmonary capillary wedge pressure; PW-TDI-s: peak systolic myocardial velocity derived by pulsed wave Doppler tissue; PW-TDI-e: peak early diastolic myocardial velocity; PW-TDI-a: peak late diastolic myocardial velocity; RWT: relative wall thickness; SWT: septal wall thickness; PWT: posterior wall thickness; sPA: pulmonary artery systolic pressure; SLE: systemic lupus erythematosus; SV: stroke volume; TAPSE: tricuspid annular plane systolic excursion; NS: not significant.

PW-TDI measurements of the lateral mitral annulus. PW-TDI revealed a reduction in the systolic as well as in the diastolic (e, a) LV function (Table 2 and Figure 1A). The ratio of E/e was elevated in the SLE group compared to controls, but the level was still near the normal range (Table 2 and Figure 1B), so no firm conclusion can be drawn. Estimated systolic pulmonary artery pressure (sPA), derived from the tricuspid regurgitation signal, was still within the normal range but was significantly elevated in the SLE group compared to healthy controls (Table 2).

Tissue Doppler and strain imaging. To render the data less




Figure 1. Comparison of myocardial structure and function in SLE patients and controls with 2-dimensional echocardiography and strain imaging. A. PW-TDI-s, peak systolic myocardial velocity derived by pulsed wave Doppler tissue, is impaired in SLE. B. Reduced diastolic function in SLE determined by E/e ratio. Peak systolic strain rate (C, SRR) and strain (D, SR) is reduced in SLE compared to controls. Values are mean \pm SD. ** $p < 0.05$

complex, to present them more clearly, and because of similar findings in different wall regions, mean values of TDI derived from all regions were calculated and are presented in Table 3. Peak systolic TDI differed between SLE patients and controls at any site ($p < 0.05$). Also, peak early and late diastolic TDI values were statistically different among the groups ($p < 0.05$). SRI and SRR clearly documented that SLE was associated with a decrease in systolic function and diastolic function in asymptomatic patients with SLE (Figure 1C and 1D).

SRI and TDI measurements were significantly reduced in all subjects with SLE. There was no significant difference in SRI in the group of patients with SLE and hypertension compared to those with SLE and without hypertension ($-15.2 \pm 2.2\%$ vs $-14.7 \pm 2.5\%$; $p = 0.43$). Also, subjects receiving hydroxychloroquine showed no significant differences ($-15.2 \pm 2.1\%$ vs $-15.1 \pm 2.5\%$; $p = 0.9$).

Analysis of disease activity. SLE patients were divided into 2 groups according to higher and lower disease activity. Interestingly, those with a higher ECLAM and SLEDAI activity score presented a significantly reduced longitudinal function, when measured with SRR and SRI (Figure 2). This difference was still clearly detectable for SRI without the

Table 3. Comparison of LV function with tissue Doppler and strain imaging in SLE patients and in controls.

	SLE, n = 67	Control, n = 40	p
Mean basal TDI, cm/s			
s	3.9 ± 1.0	5.1 ± 0.8	< 0.05
e	6.2 ± 1.8	8.4 ± 1.7	< 0.05
a	3.7 ± 0.8	4.3 ± 1.1	< 0.05
Mean global TDI, cm/s			
s	2.9 ± 0.9	3.9 ± 0.7	< 0.05
e	4.3 ± 1.5	6.3 ± 1.3	< 0.05
a	2.9 ± 0.8	3.4 ± 0.8	< 0.05
Mean strain rate, s^{-1}			
s	-0.8 ± 0.1	-1.1 ± 0.1	< 0.05
e	1.1 ± 0.2	1.6 ± 0.3	< 0.05
a	0.7 ± 0.1	1.0 ± 0.2	< 0.05
Regional strain, %			
Inferoseptal	15.7 ± 2.8	19.6 ± 2.3	< 0.05
Anterolateral	14.5 ± 2.2	19.0 ± 2.4	< 0.05
Anterior	14.6 ± 2.6	19.8 ± 2.4	< 0.05
Inferior	16.2 ± 2.8	20.9 ± 2.9	< 0.05
Inferolateral	14.6 ± 2.3	19.2 ± 2.0	< 0.05
Global strain, %	15.1 ± 2.2	19.7 ± 1.9	< 0.05

s: peak systolic myocardial velocity; e: peak early diastolic myocardial velocity; a: peak late diastolic myocardial velocity, as derived by tissue Doppler or SRR.




Figure 2. Evaluation of left ventricular longitudinal function in SLE patients with lower and higher disease activity using the ECLAM (A and B) and the SLEDAI score (C and D). A, C: peak systolic strain rate (SRR); B, D: peak systolic strain (SR). *p < 0.05 vs control, **p < 0.05 vs Low, #p < 0.05 vs Low.

patients with SLE plus hypertension ($p < 0.05$). Of note, there was still a significant difference between subjects with low disease activity and control subjects (Figure 2). The measurements of TDI and PW-TDI could not differentiate between subjects with higher versus lower disease activity ($p = 0.83$ and $p = 0.49$). LV mass indices also did not show an association with disease activity (data not shown). Measurements of CRP, ESR, and dsDNA antibodies did not correlate significantly with longitudinal function ($p = 0.4$, $p = 0.07$, and $p = 0.9$, respectively). Thus SRI performed better than TDI in detecting differences of longitudinal systolic function in SLE regarding disease activity.

Observer variabilities. The intraobserver variabilities were 6.5% for TDI, 8.0% for SRR, and 5.9% for SR. The interobserver variabilities were 7.5% for TDI, 8.3% for SRR, and 6.3% for SR.

Strain parameters showed good reproducibility (intra- and interobserver variability) for SRR ($r = 0.85$ and 0.80 , respectively) and SR ($r = 0.85$ and 0.79).

DISCUSSION

Our study shows that young patients with SLE, even in the absence of specific clinical complaints of heart disease, demonstrate abnormal systolic and diastolic LV longitudinal

function. Tissue Doppler and strain imaging are accurate means to determine myocardial dysfunction, providing incremental findings in stages of the disease, where 2D echocardiography shows normal findings.

TDI and SRI are noninvasive techniques, widely used to detect subtle, asymptomatic myocardial functional abnormalities. They are useful and early indicators of LV dysfunction and allow a reliable screening for subclinical cardiac manifestations in patients with increased risk for cardiovascular diseases^{21,41}. Our study suggests that these methods may be used in patients with SLE and can provide important further information.

Patients with SLE have an increased prevalence of subclinical LV dysfunction, which may be a prognostic indicator of cardiac morbidity and mortality. Mechanisms by which SLE might directly induce changes in LV structure and function are manifold and include underlying inflammatory processes leading to subclinical vasculitis, myocarditis or vascular stiffening, and preclinical CAD in SLE patients^{7,8,42}.

Myocarditis is a characteristic feature of myocardial involvement in SLE⁴³. However, since the advent of corticosteroid therapy, vasculitis and myocarditis have been rare findings in SLE patients who undergo autopsy⁴⁴. Currently,

myocarditis is reported in 7%–10% of cases. However, subclinical involvement for other cardiac manifestations is probably more frequent. Echocardiography findings, while not specific and sensitive, are suggestive of myocardial inflammation: observations include global or regional wall motion abnormalities, decreased ejection fraction, increased chamber size, and prolonged isovolumic relaxation time⁴⁵. Cardiac magnetic resonance imaging (MRI) demonstrated that T2 relaxation times were significantly longer in patients with active SLE compared to healthy controls; such abnormalities are a sensitive indicator of myocardial disease even in the absence of myocardial involvement by clinical criteria⁴⁶. Scintigraphy and MRI may be useful in the diagnosis of myocardial inflammation and myocarditis but are usually not used as a screening method in clinical routine.

Myocardial dysfunction in SLE may also be the consequence of other features, particularly CAD due to premature atherosclerosis, hypertension, renal failure, valvular disease, and toxicity from medications such as chloroquine^{7,8,47}. But little is known about the prevalence of preclinical disease and associated factors. Previous evidence from autopsies and clinical studies has suggested that the prevalence of subclinical atherosclerosis is increased in patients with SLE⁴⁷. Ventricular remodeling and subsequent LV functional changes may therefore result from premature development of atherosclerosis^{48,49}. In SLE, reported CAD prevalence ranges from 6% to 10%^{7,50}; and in young women, risk of myocardial infarction is increased 50-fold. These results are concordant with those of a retrospective study in which risk of adverse cardiovascular outcomes was observed to be increased by a factor of 7 to 17 in patients with SLE as compared with the Framingham cohort⁵¹. Different mechanisms play a role in the development of CAD. These include atherosclerosis of epimyocardial coronary arteries, coronary arteritis, thrombotic events, or vasospasm. Attempts to address the extent and severity of CAD in patients with SLE more directly have used single-photon-emission computed tomography (SPECT), detecting myocardial perfusion abnormalities in 35% of patients⁵². In previous studies, Tc-99m sestamibi myocardial perfusion SPECT showed high incidence of myocardial perfusion abnormalities in asymptomatic lupus patients without any clinical signs of cardiac involvement⁵³. Whether SRI is valuable for the diagnosis or prognosis of CAD in SLE patients should be evaluated in further comparative prospective studies.

Alterations in LV structure and function have also been reported as cardiac manifestations of SLE, including echocardiographic evidence of increased LV wall thicknesses and LV mass, a decrease in LV ejection fraction, and impaired diastolic filling^{5,32,40,45}. Although no SLE patients in our study had clinical signs of ischemic heart disease, decreased longitudinal LV function in SLE patients might be a reflection of preclinical ischemic myocardial disease. The use of tissue Doppler and strain imaging has shown a sig-

nificant reduction of systolic and diastolic function of the LV, despite normal ejection fraction and cardiac output. Gradation was not noticeable for DT but was observed for E/e ratio, the prime parameter reflecting diastolic dysfunction. Our results are in agreement with the findings of Lee, *et al*, Sasson, *et al*, and Fujimoto, *et al*, who demonstrated a high incidence of LV diastolic dysfunction in patients with SLE^{32,33,48}. Gin, *et al*³⁴ used TDI to evaluate heart function in patients with SLE. A trend towards LV dysfunction was also observed in the SLE group. LV ejection fraction and peak systolic TDI of the mitral annulus was lower in SLE; however, this trend was not statistically significant. In a more detailed study by Crozier, *et al*⁵, greater LV wall thicknesses and mass and lower ejection fraction were found in 50 SLE patients compared with controls. In accord with our results, Yip and colleagues⁵⁴ recently reported that patients with SLE had subclinical long and short-axis dysfunctions, using TDI of the basal segments of the LV. As described above, SR and SRR were reduced in our study, indicative of a form of heart failure with preserved ejection fraction. Also, Chow, *et al* recently showed significantly reduced longitudinal function detected by SRI values in young adolescents with pediatric-onset SLE³¹. In contrast to that study, we investigated young adults without pediatric-onset SLE. In addition to the significant findings, we focused further on LV longitudinal dysfunction in SLE. Of note, we observed that reduction of longitudinal myocardial dysfunction was associated with higher disease activity scores. SLE, in addition to traditional stimuli, augments LV dysfunction, possibly by a direct disease-related effect of SLE on LV structure and function.

In conclusion, asymptomatic patients with SLE already have reduced systolic and diastolic LV longitudinal function. Longitudinal LV function is significantly associated with enhanced disease activity. Damage of the LV seems to have multiple causes and thus implies a careful clinical evaluation of these patients. The clinical significance of this dysfunction needs to be established in longterm studies to determine whether detection of such abnormalities in otherwise asymptomatic subjects should affect their therapeutic management. Moreover, use of modern imaging techniques could advance our understanding of the prevalence and mechanisms of heart involvement in patients with SLE.

REFERENCES

1. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. *J Rheumatol* 1995;22:1259-64.
2. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. *Arthritis Rheum* 1999;42:338-46.
3. Dubois EL, Tuffanelli DL. Clinical manifestations of systemic lupus erythematosus. Computer analysis of 520 cases. *JAMA* 1964;190:104-11.
4. Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, et al. Prevalence and risk factors of carotid plaque in

- women with systemic lupus erythematosus. *Arthritis Rheum* 1999;42:51-60.
5. Crozier IG, Li E, Milne MJ, Nicholls MG. Cardiac involvement in systemic lupus erythematosus detected by echocardiography. *Am J Cardiol* 1990;65:1145-8.
 6. Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. *Lupus* 2005;14:683-6.
 7. Abusamieh M, Ash J. Atherosclerosis and systemic lupus erythematosus. *Cardiol Rev* 2004;12:267-75.
 8. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. *N Engl J Med* 2003;349:2407-15.
 9. Fairfax MJ, Osborn TG, Williams GA, Tsai CC, Moore TL. Endomyocardial biopsy in patients with systemic lupus erythematosus. *J Rheumatol* 1988;15:593-6.
 10. Kocica MJ, Corno AF, Carreras-Costa F, Ballester-Rodes M, Moghbel MC, Cueva CN, et al. The helical ventricular myocardial band: global, three-dimensional, functional architecture of the ventricular myocardium. *Eur J Cardiothorac Surg* 2006;29 Suppl 1:S21-40.
 11. Torrent Guasp F. [Macroscopic structure of the ventricular myocardium]. *Rev Esp Cardiol* 1980;33:265-87.
 12. Wandt B. Long-axis contraction of the ventricles: a modern approach, but described already by Leonardo da Vinci. *J Am Soc Echocardiogr* 2000;13:699-706.
 13. Gilbert SH, Benson AP, Li P, Holden AV. Regional localisation of left ventricular sheet structure: integration with current models of cardiac fibre, sheet and band structure. *Eur J Cardiothorac Surg* 2007;32:231-49.
 14. Willenheimer R, Cline C, Erhardt L, Israelsson B. Left ventricular atrioventricular plane displacement: an echocardiographic technique for rapid assessment of prognosis in heart failure. *Heart* 1997;78:230-6.
 15. Wang M, Yip GW, Wang AY, Zhang Y, Ho PY, Tse MK, et al. Peak early diastolic mitral annulus velocity by tissue Doppler imaging adds independent and incremental prognostic value. *J Am Coll Cardiol* 2003;41:820-6.
 16. Wang M, Yip GW, Wang AY, Zhang Y, Ho PY, Tse MK, et al. Tissue Doppler imaging provides incremental prognostic value in patients with systemic hypertension and left ventricular hypertrophy. *J Hypertens* 2005;23:183-91.
 17. Svealv BG, Olofsson EL, Andersson B. Ventricular long-axis function is of major importance for long-term survival in patients with heart failure. *Heart* 2008;94:284-9.
 18. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. *Arthritis Rheum* 1992;35:630-40.
 19. Nossent JC. Course and prognostic value of Systemic Lupus Erythematosus Disease Activity Index in black Caribbean patients. *Semin Arthritis Rheum* 1993;23:16-21.
 20. Carlsson M, Ugander M, Mosen H, Buhre T, Arheden H. Atrioventricular plane displacement is the major contributor to left ventricular pumping in healthy adults, athletes, and patients with dilated cardiomyopathy. *Am J Physiol Heart Circ Physiol* 2007;292:H1452-9.
 21. Abraham TP, Dimaano VL, Liang HY. Role of tissue Doppler and strain echocardiography in current clinical practice. *Circulation* 2007;116:2597-609.
 22. Henein MY, Anagnostopoulos C, Das SK, O'Sullivan C, Underwood SR, Gibson DG. Left ventricular long axis disturbances as predictors for thallium perfusion defects in patients with known peripheral vascular disease. *Heart* 1998;79:295-300.
 23. Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. *Circulation* 2003;107:2446-52.
 24. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. *J Am Coll Cardiol* 1998;32:865-75.
 25. Katz WE, Gulati VK, Mahler CM, Gorcsan J 3rd. Quantitative evaluation of the segmental left ventricular response to dobutamine stress by tissue Doppler echocardiography. *Am J Cardiol* 1997;79:1036-42.
 26. von Bibra H, Tchnitz A, Klein A, Schneider-Eicke J, Schomig A, Schwaiger M. Regional diastolic function by pulsed Doppler myocardial mapping for the detection of left ventricular ischemia during pharmacologic stress testing: a comparison with stress echocardiography and perfusion scintigraphy. *J Am Coll Cardiol* 2000;36:444-52.
 27. Wilkenshoff UM, Sovany A, Wigstrom L, Olstad B, Lindstrom L, Engvall J, et al. Regional mean systolic myocardial velocity estimation by real-time color Doppler myocardial imaging: a new technique for quantifying regional systolic function. *J Am Soc Echocardiogr* 1998;11:683-92.
 28. Nagueh SF, Bachinski LL, Meyer D, Hill R, Zoghbi WA, Tam JW, et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. *Circulation* 2001;104:128-30.
 29. Heimdal A, Stoylen A, Torp H, Skjaerpe T. Real-time strain rate imaging of the left ventricle by ultrasound. *J Am Soc Echocardiogr* 1998;11:1013-9.
 30. Urheim S, Edvardsen T, Torp H, Angelsen B, Smiseth OA. Myocardial strain by Doppler echocardiography. Validation of a new method to quantify regional myocardial function. *Circulation* 2000;102:1158-64.
 31. Chow PC, Ho MH, Lee TL, Lau YL, Cheung YF. Relation of arterial stiffness to left ventricular structure and function in adolescents and young adults with pediatric-onset systemic lupus erythematosus. *J Rheumatol* 2007;34:1345-52.
 32. Lee SW, Park MC, Park YB, Lee SK. E/E' ratio is more sensitive than E/A ratio for detection of left ventricular diastolic dysfunction in systemic lupus erythematosus. *Lupus* 2008;17:195-201.
 33. Sasson Z, Rasooly Y, Chow CW, Marshall S, Urowitz MB. Impairment of left ventricular diastolic function in systemic lupus erythematosus. *Am J Cardiol* 1992;69:1629-34.
 34. Gin PL, Wang WC, Yang SH, Hsiao SH, Tseng JC. Right heart function in systemic lupus erythematosus: insights from myocardial Doppler tissue imaging. *J Am Soc Echocardiogr* 2006;19:441-9.
 35. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982;25:1271-7.
 36. Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. *Clin Exp Rheumatol* 1992;10:541-7.
 37. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. *J Am Soc Echocardiogr* 2005;18:1440-63.
 38. de Simone G, Gottdiener JS, Chinali M, Maurer MS. Left

- ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. *Eur Heart J* 2008;29:741-7.
39. Bella JN. Indexation of left ventricular mass to identify blood pressure-related left ventricular hypertrophy. *Am J Hypertens* 2005;18:1263-5.
 40. Pieretti J, Roman MJ, Devereux RB, Lockshin MD, Crow MK, Paget SA, et al. Systemic lupus erythematosus predicts increased left ventricular mass. *Circulation* 2007;116:419-26.
 41. Yu CM, Sanderson JE, Marwick TH, Oh JK. Tissue Doppler imaging: a new prognosticator for cardiovascular diseases. *J Am Coll Cardiol* 2007;49:1903-14.
 42. Manger K, Kusus M, Forster C, Ropers D, Daniel WG, Kalden JR, et al. Factors associated with coronary artery calcification in young female patients with SLE. *Ann Rheum Dis* 2003;62:846-50.
 43. Doherty NE, Siegel RJ. Cardiovascular manifestations of systemic lupus erythematosus. *Am Heart J* 1985;110:1257-65.
 44. Bidani AK, Roberts JL, Schwartz MM, Lewis EJ. Immunopathology of cardiac lesions in fatal systemic lupus erythematosus. *Am J Med* 1980;69:849-58.
 45. Omdal R, Lunde P, Rasmussen K, Mellgren SI, Husby G. Transesophageal and transthoracic echocardiography and Doppler-examinations in systemic lupus erythematosus. *Scand J Rheumatol* 2001;30:275-81.
 46. Singh JA, Woodard PK, Davila-Roman VG, Waggoner AD, Gutierrez FR, Zheng J, et al. Cardiac magnetic resonance imaging abnormalities in systemic lupus erythematosus: a preliminary report. *Lupus* 2005;14:137-44.
 47. Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. *Ann Rheum Dis* 2003;62:1071-7.
 48. Fujimoto S, Kagoshima T, Nakajima T, Dohi K. Doppler echocardiographic assessment of left ventricular diastolic function in patients with systemic lupus erythematosus. *Cardiology* 1994;85:267-72.
 49. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. *N Engl J Med* 2003;349:2399-406.
 50. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. *Am J Med* 1992;93:513-9.
 51. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. *Arthritis Rheum* 2001;44:2331-7.
 52. Bruce IN, Burns RJ, Gladman DD, Urowitz MB. Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. I. Prevalence and distribution of abnormalities. *J Rheumatol* 2000;27:2372-7.
 53. Schillaci O, Lagana B, Danieli R, Gentile R, Tubani L, Baratta L, et al. Technetium-99m sestamibi single-photon emission tomography detects subclinical myocardial perfusion abnormalities in patients with systemic lupus erythematosus. *Eur J Nucl Med* 1999;26:713-7.
 54. Yip GW, Shang Q, Tam LS, Zhang Q, Li EK, Fung JW, et al. Disease chronicity and activity predicts subclinical left ventricular systolic dysfunction in patients with systemic lupus erythematosus. *Heart* 2009;95:980-7.